These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
77 related articles for article (PubMed ID: 1525610)
21. Recombinant interleukin-2 (rIL-2) after autologous bone marrow transplantation (BMT): a pilot study in 19 patients. Blaise D; Viens P; Olive D; Stoppa AM; Gabert J; Pourreau CN; Attal M; Gaspard MH; Mannoni P; Jasmin C Eur Cytokine Netw; 1991; 2(2):121-9. PubMed ID: 1813015 [TBL] [Abstract][Full Text] [Related]
22. Early infections in patients undergoing bone marrow or blood stem cell transplantation--a 7 year single centre investigation of 409 cases. Krüger W; Rüssmann B; Kröger N; Salomon C; Ekopf N; Elsner HA; Kaulfers PM; Mack D; Fuchs N; Dürken M; Kabisch H; Erttmann R; Zander AR Bone Marrow Transplant; 1999 Mar; 23(6):589-97. PubMed ID: 10217190 [TBL] [Abstract][Full Text] [Related]
23. Infections in allogeneic bone marrow transplant recipients. Wingard JR Semin Oncol; 1993 Oct; 20(5 Suppl 6):80-7. PubMed ID: 8211220 [TBL] [Abstract][Full Text] [Related]
24. Close simulation of acute graft-versus-host disease by interleukin-2 administered after autologous bone marrow transplantation for hematologic malignancy. Massumoto C; Benyunes MC; Sale G; Beauchamp M; York A; Thompson JA; Buckner CD; Fefer A Bone Marrow Transplant; 1996 Mar; 17(3):351-6. PubMed ID: 8704686 [TBL] [Abstract][Full Text] [Related]
25. [Current possibilities in immunotherapy of cancer]. von Fliedner V Schweiz Med Wochenschr; 1987 Feb; 117(7):243-8. PubMed ID: 3551061 [TBL] [Abstract][Full Text] [Related]
26. Antileukemic effect of interleukin-2-transduced murine bone marrow after autologous transplantation. Tam YK; Klingemann HG Biol Blood Marrow Transplant; 1999; 5(4):231-42. PubMed ID: 10465103 [TBL] [Abstract][Full Text] [Related]
27. Antileukemic effect of interleukin-2-transduced murine bone marrow after autologous transplantation. Tam YK; Klingemann HG Biol Blood Marrow Transplant; 1999; 5(3):144-54. PubMed ID: 10392960 [TBL] [Abstract][Full Text] [Related]
28. Low-dose interleukin-2 therapy is not associated with cutaneous toxicity after autologous transplantation. López-Jiménez J; De las Heras E; Hilara Y; García-Laraña J; Pérez-Oteyza J; Bellas C; Muñoz A; Rocamora A; Núñez M; Odriozola J Bone Marrow Transplant; 1996 Aug; 18(2):481-2. PubMed ID: 8864471 [No Abstract] [Full Text] [Related]
29. G-CSF after autologous bone marrow transplantation for malignant diseases in children. Spanish Working Party for Bone Marrow Transplantation in Children. Madero L; Muõnz A; Diaz de Heredia A; Martínez A; Badell I; Esquembre C; Ramírez M; Otheo E; Olive A; Sastre A Bone Marrow Transplant; 1995 Mar; 15(3):349-51. PubMed ID: 7541268 [TBL] [Abstract][Full Text] [Related]
30. Bloodstream infections can develop late (after day 100) and/or in the absence of neutropenia in children receiving allogeneic bone marrow transplantation. Romano V; Castagnola E; Dallorso S; Lanino E; Calvi A; Silvestro S; Morreale G; Giacchino R; Dini G Bone Marrow Transplant; 1999 Feb; 23(3):271-5. PubMed ID: 10084259 [TBL] [Abstract][Full Text] [Related]
31. Infection prevention in autologous bone marrow transplantation and the role of protective isolation. Dekker AW; Verdonck LF; Rozenberg-Arska M Bone Marrow Transplant; 1994 Jul; 14(1):89-93. PubMed ID: 7951125 [TBL] [Abstract][Full Text] [Related]
32. Interleukin-2 in autologous bone marrow transplantation. Charak BS Natl Med J India; 1993; 6(1):19-22. PubMed ID: 8453356 [TBL] [Abstract][Full Text] [Related]
33. Cutaneous hypersensitivity to co-trimoxazole after autologus bone marrow transplantation and immunotherapy with interferon alpha-2A and interleukin-2. Mehta J; Nagler A; Ackerstein A; Kapelushnik J; Or R J Assoc Physicians India; 1993 Apr; 41(4):235-6. PubMed ID: 8270579 [TBL] [Abstract][Full Text] [Related]
34. [Infection in the patient undergoing bone marrow transplantation]. Carratalá J; Fernàndez-Sevilla A; Gudiol F Enferm Infecc Microbiol Clin; 1997 May; 15 Suppl 2():51-6. PubMed ID: 9312299 [No Abstract] [Full Text] [Related]
35. Infection in the bone marrow transplant recipient. Walter EA; Bowden RA Infect Dis Clin North Am; 1995 Dec; 9(4):823-47. PubMed ID: 8747768 [TBL] [Abstract][Full Text] [Related]
36. IL2 activated killer cells may contribute to cytomegalovirus induced marrow hypoplasia after bone marrow transplantation. Duncombe AS; Grundy JE; Prentice HG; Brenner MK Bone Marrow Transplant; 1991 Feb; 7(2):81-7. PubMed ID: 1646663 [TBL] [Abstract][Full Text] [Related]
37. [Measures for the prevention of infections in patients with bone marrow transplantations]. Rasero L; Errico A; Bertelli A Riv Inferm; 1997; 16(3):139-43. PubMed ID: 9460461 [TBL] [Abstract][Full Text] [Related]
38. Progression of natural immunity during one-year treatment of residual disease in neuroblastoma patients with high doses of interleukin-2 after autologous bone marrow transplantation. Martí F; Pardo N; Peiró M; Bertran E; Amill B; García J; Cubells J; Rueda F Exp Hematol; 1995 Dec; 23(14):1445-52. PubMed ID: 8542930 [TBL] [Abstract][Full Text] [Related]
39. Clinical and biological effects of gamma interferon and the combination of gamma interferon and interleukin-2 after autologous bone marrow transplantation. Vey N; Viens P; Fossat C; Olive D; Sainty D; Baume D; Stoppa AM; Bouabdallah R; Brandely M; Gastaut JA; Maraninchi D; Blaise D Eur Cytokine Netw; 1997 Dec; 8(4):389-94. PubMed ID: 9459619 [TBL] [Abstract][Full Text] [Related]
40. Prophylaxis and pre-emptive therapy of bacterial infections following allogeneic bone marrow transplantation in children. Vossen JM; de Tollenaer S; van Weel-Sipman MH Bone Marrow Transplant; 1996 Nov; 18 Suppl 2():93-6. PubMed ID: 8932807 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]